CG Oncology (CGON) Liabilities and Shareholders Equity (2023 - 2026)

CG Oncology has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 55.9% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $3.4 billion (up 29.17% YoY), and the FY2025 full-year result was $791.6 million, up 4.87% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.1 billion, up from $791.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.1 billion in Q1 2026, with the low at $199.3 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $673.6 million across 4 years, with a median of $714.8 million in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 278.72% — and 2025, when it gained 4.87%.
• CG Oncology's Liabilities and Shareholders Equity stood at $199.3 million in 2023, then soared by 278.72% to $754.8 million in 2024, then grew by 4.87% to $791.6 million in 2025, then jumped by 43.42% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $791.6 million (Q4 2025), and $729.9 million (Q3 2025), per Business Quant data.